EMEA-002681-PIP01-19-M01
Key facts
| Active substance |
Rozanolixizumab
|
| Therapeutic area |
Neurology
|
| Decision number |
P/0410/2022
|
| PIP number |
EMEA-002681-PIP01-19-M01
|
| Pharmaceutical form(s) |
Solution for injection
|
| Condition(s) / indication(s) |
Treatment of myasthenia gravis
|
| Route(s) of administration |
Subcutaneous use
|
| Contact for public enquiries |
UCB Pharma S.A.
E-mail: UCBCares.IE@ucb.com |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|